Loading ...
Sorry, an error occurred while loading the content.

FW: NATAP: Vertex Hepatitis C Protease Inhibitor

Expand Messages
  • alleypat
    Vertex shoots up on hepatitis C results By Val Brickates Kennedy, MarketWatch Last Update: 5:53 PM ET Feb. 7, 2006 BOSTON (MarketWatch) -- Shares of Vertex
    Message 1 of 1 , Feb 8, 2006
      Vertex shoots up on hepatitis C results

      By Val Brickates Kennedy, MarketWatch
      Last Update: 5:53 PM ET Feb. 7, 2006

      BOSTON (MarketWatch) -- Shares of Vertex Pharmaceuticals shot up Tuesday
      after it released highly favorable clinical results for its hepatitis C drug
      candidate, VX-950.

      Before the market's open, the company said that preliminary Phase II results
      showed that none of the 12 patients in the trial who used VX-950 in
      combination with two other leading hepatitis C drugs showed any tangible
      sign of the virus in their bloodstream after 28 days.

      Vertex had tested VX-950 with the drugs pegylated interferon alfa-2a and
      ribavirin, current standards in treating the life-threatening liver disease.
      The 28-day study was not designed to measure how long the immune response
      could be sustained, according to the company.

      Vertex plans to unveil full results from the study at medical conference
      later this year.

      According to Vertex Pharmaceuticals chief executive officer Joshua Boger,
      the results were surprisingly good.

      "No one has seen these results before with any regimen over any period of
      time," said Boger. "They can't get any better."

      Currently, hepatitis C sufferers must undergo a one-year regimen of the
      pegylated interferon and ribavirin in order to try to rid their bodies of
      the virus. The regimen, which can be physically debilitating, only has about
      a 50% success rate.

      Boger said that the company will use the data to help design much larger,
      longer Phase II clinical trials. As Vertex has been awarded fast-track
      status for the drug, the company will submit the information to the Food and
      Drug Administration by the end of the first quarter for its feedback on how
      the trials should be designed.

      In particular, said Boger, the company wants to test to see if VX-950, in
      combination with pegylated interferon, can keep the body virus-free for at
      least three months. Vertex might also run longer-term tests of the drugs in
      combination with ribavirin.

      Because hepatitis C has few treatment options, analysts have estimated the
      worldwide market for drugs such as VX-950 could be as high as $8 billion. If
      the clinical trials go smoothly, Vertex has said it could be ready to file
      for FDA approval in 2008.

      The Cambridge, Mass.-based biotech firm will release its fourth-quarter
      earnings after the market's close Tuesday. It's expected to post a loss of
      23 cents a share, compared with a loss of 38 cents a share last year,
      according to a survey by Thomson First Call.

      Hoping a Small Sample May Signal a Cure
      Vertex Hep C Protease Inhibitor

      NY Times
      February 7, 2006
      Market Place

      Joshua Boger might have finally found his billion-dollar molecule.

      Mr. Boger, the brash founder and chief executive of Vertex Pharmaceuticals,
      was profiled, along with his company, in a 1994 book "The Billion-Dollar
      Molecule: One Company's Quest for the Perfect Drug." But the drug discussed
      in the book never made it to market, and after more than 16 years in
      business and losses totaling about $1 billion, Vertex has still not hit it

      Now, though, the company's hopes, and its stock price, are soaring because
      of a drug to treat hepatitis C, a liver-destroying virus that infects about
      three million Americans, kills 10,000 of them a year and is the leading
      reason for liver transplants in this country.

      Vertex is expected to announce today that when its drug, VX-950, was added
      to current common therapy, the virus became undetectable in the blood of all
      12 patients tested after four weeks. The results could buttress the
      company's case that the drug will reduce treatment time for the toughest
      strain of the virus to three months, compared with about a year under
      current treatments.

      "We haven't seen data like this before, where everybody's negative so early
      on in treatment," said Dr. John G. McHutchison, a professor at Duke and a
      coordinator of VX-950 trials. Dr. McHutchison, a consultant to Vertex and
      many other companies, said that the existing therapy reduced the virus to an
      undetectable level in only about 30 percent of patients after a four-week

      The new results could further invigorate Vertex's stock price, which has
      tripled since May, when the company released its first VX-950 data, based on
      two weeks of testing. Vertex shares closed yesterday at $34.30, down 24

      For all the drug's promise, though, some analysts emphasize that the results
      are from a very small sample of patients in early-stage clinical trials, and
      that the stock may be getting ahead of itself. Some are also wary of Mr.
      Boger's reputation as a zealous cheerleader. The company has had to abandon
      what it hoped were promising drugs in the past.

      At a J. P. Morgan health care conference in San Francisco last month, Mr.
      Boger began his talk on VX-950 by showing a picture of the Apple iPod.
      "Every so often," he said, "there's a game-changing product - one that
      transforms a product category, one that transforms a company and one that
      transforms an industry."

      Later, he compared Vertex to Thomas A. Edison's laboratory and concluded,
      "This astounding data can actually be a bit terrifying."

      VX-950 is at the forefront of a new approach in attacking the hepatitis C
      virus by using techniques that have had great success against H.I.V., the
      virus that causes AIDS. Many doctors who treat hepatitis C are as excited as
      Wall Street has been by VX-950 and other drugs like it under development.

      If the drugs work, said Dr. Eugene Schiff, chief of hepatology at the
      University of Miami and a consultant to many companies, "more people will
      achieve a sustained viral response over a shorter period of time with fewer
      side effects." Such a response, in which the virus remains undetectable six
      months after treatment ends, is considered by scientists to be evidence of a

      But so far, VX-950 has not achieved any sustained viral responses. "I
      haven't cured a patient yet," Mr. Boger said in an interview.

      The company has released data on fewer than 60 patients, each treated for
      two or four weeks. Side effects that could derail the drug may pop up as it
      is tested for longer durations in more people. And other companies,
      including the much larger Schering-Plough, are developing similar drugs.

      In November, David Witzke, an analyst at Banc of America Securities, lowered
      Vertex's stock rating to sell, saying that the company had been overly
      aggressive in predicting that it would be able to apply for federal approval
      of VX-950 in 2008.

      He also noted that Vertex was being valued in the same range as ImClone
      Systems and Amylin Pharmaceuticals, companies with substantial revenue from
      drugs already on the market. Vertex's market capitalization is now around
      $3.4 billion.

      Hepatitis C can cause cirrhosis and liver cancer, though these might not
      occur until decades after infection. The virus is transmitted by
      contaminated needles, blood transfusions and less often, sexually.

      With donated blood now being screened for the hepatitis C virus, virtually
      eliminating that source of infection, only about 25,000 new infections a
      year occur in the United States. But because of the large number of baby
      boomers infected years ago, specialists estimate that the number of deaths
      from hepatitis C will triple in coming years, to 30,000 annually. The
      problem is greater outside the United States, with an estimated 170 million
      infected globally.

      The current treatment is alpha interferon - either Roche's Pegasys or
      Schering-Plough's Peg-Intron - combined with ribavirin, which was developed
      by Valeant Pharmaceuticals but is now generic.

      Patients must inject themselves with interferon once a week for 24 weeks or
      for 48 weeks, depending on the strain of virus. The treatment can cost
      $30,000 and have severe side effects, including flu-like symptoms and
      depression. Only about half those treated are cured.

      Sales of hepatitis C treatments in the United States are now about $1
      billion, Mr. Boger said. But if the treatment could be made quicker and more
      tolerable, as with VX-950, he said that such sales could grow to a range of
      $3 billion to $5 billion.

      Vertex's drug and similar ones come in pill form. And while interferon and
      ribavirin are thought to work mainly by spurring the body's immune system to
      attack the virus, the newer drugs attack the virus directly by inhibiting
      enzymes it needs to replicate.

      VX-950 inhibits the hepatitis C protease enzyme. Some other companies, led
      by Idenix Pharmaceuticals, are focused on another enzyme, polymerase. Most
      H.I.V. drugs similarly inhibit one of two enzymes - protease or reverse

      Despite the strong early results for VX-950, there is already some evidence
      that the virus can rebound, evolving to become resistant to the drug.

      Mr. Boger said that using VX-950 with interferon would slow viral
      replication so much that resistance was not likely to develop. Patients
      would still have to endure interferon injections, though experts say that
      eventually combinations of newer drugs would suffice.

      Another question is whether Vertex will be first. Schering-Plough, which
      also has a protease inhibitor, started Phase 2 trials last fall, a few
      months ahead of Vertex. But its drug did not produce as sharp a drop in
      viral levels in its two-week trial as Vertex's did.

      "The Vertex protease looks to be the strongest," said Dr. Robert G. Gish,
      medical director of the liver-transplant program at California Pacific
      Medical Center in San Francisco.

      Moreover, Schering-Plough is testing its drug for 6 or 12 months, like the
      standard therapies. Vertex is gambling that it can leap ahead with tests
      lasting only three months.

      Dr. Douglas Dieterich, a liver-disease specialist at Mount Sinai School of
      Medicine in Manhattan, termed that "very optimistic." He said he thought it
      would take longer to train the immune system to control the virus.

      Analysts infer that Boehringer Ingelheim and Bristol-Myers Squibb have also
      begun early clinical trials of hepatitis C protease inhibitors. InterMune
      has two compounds in the laboratory.

      Asked who was ahead, Dr. Schiff at the University of Miami replied that
      "there are a lot of people on the same playing field."

      Andrew McDonald, an analyst at ThinkEquity Partners, said Vertex was worth
      no more than $30 a share based on VX-950 alone. But he recently upgraded the
      stock to buy with a $40 price target, based on another potential blockbuster
      drug he said had been overlooked by Wall Street.

      That drug, VX-702, is aimed at treating rheumatoid arthritis by inhibiting
      an enzyme known as P-38. This is a hot area for drug companies, but many
      P-38 inhibitors caused unacceptable side effects.

      VX-702 is chemically different, Mr. McDonald said. "It looks like Vertex has
      the lead with a compound that may escape the shortcomings of many of the
      dozen or so that have failed before it," he said. Results from a midstage
      trial of VX-702 are expected in the second quarter.

      If either drug pans out, some analysts predict that Vertex will be acquired
      by a larger company.

      Success would also mean vindication for Mr. Boger, who has a doctorate in
      chemistry from Harvard. He was a rising star at Merck until leaving in 1989
      to start Vertex, whose founding premise was to design drugs suited to a
      target in the body, rather than screen thousands of compounds at random, a
      standard industry practice.

      "The Billion-Dollar Molecule," by a journalist, Barry Werth, portrayed the
      egos and ambitions involved in the quest for scientific glory and financial
      gain. At one point in the book, Mr. Boger, settling for a tie in a race with
      a rival, is quoted nonetheless as saying, "I want to rub his nose in the
      dirt and step on his head."

      Vertex has developed two AIDS drugs, Agenerase and a variant, Lexiva, that
      are sold by GlaxoSmithKline. They have been only modest sellers, and the
      royalties Vertex receives - $23.1 million in the first nine months of 2005 -
      have been far too small to make the company profitable.

      But Vertex, unlike many other biotechnology companies, has never put all its
      effort behind one drug. It is developing treatments for cancer, cystic
      fibrosis and pain in addition to hepatitis and arthritis. It has
      partnerships with many big pharmaceutical companies.

      "Right now they've got two potential blockbusters," said Jay Markowitz, an
      analyst at T. Rowe Price, one of the largest shareholders in Vertex. "Boger
      is a very smart scientist. He's hopefully got the company to a significant
      inflection point right now."


      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.

      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.